Endocrine cardiomyopathies: a frequently forgotten etiology

Medicina y Laboratorio

View Publication Info
 
 
Field Value
 
Title Endocrine cardiomyopathies: a frequently forgotten etiology
Cardiopatías de origen endocrino: una etiología frecuentemente olvidada
 
Creator Duque-González, Laura
Ruiz-Velásquez, Luis Miguel
Torres-Grajales, José Luis
Duque-Ramírez, Mauricio
 
Subject Cardiomyopathy, heart failure, acromegaly, Cushing’s syndrome, hypothyroidism, hyperparathyroidism.
cardiopatía, insuficiencia cardíaca, acromegalia, enfermedad de Cushing, hipotiroidismo, hiperparatiroidismo.
 
Description Endocrine diseases comprise a broad spectrum of high prevalence hormonal disorders that report significant morbidity and mortality rates. Its association with strong cardiovascular outcomes such as acute myocardial infarction, cerebrovascular disease and end-stage renal failure are clearly established; however, its relation to heart disease is frequently underestimated by medical personnel. Pituitary disorders, particularly acromegaly, hyperthyroidism, hypothyroidism and adrenal disorders, such as Cushing’s syndrome, hyperaldosteronism and pheochromocytoma, are associated with the appearance of heart failure, dilated heart disease, cardiac arrhythmias and even sudden death. The following review aims to clearly and precisely describe the main heart conditions associated with endocrine disorders.
Las enfermedades endocrinas comprenden un amplio espectro de trastornos hormonales de alta prevalencia, que reportan importantes tasas de morbimortalidad. Su asociación con desenlaces fuertes cardiovasculares, tales como infarto agudo de miocardio, enfermedad cerebrovascular e insuficiencia renal terminal, está claramente establecida; sin embargo, su relación con las cardiopatías es frecuentemente desestimada por el personal médico. Las alteraciones hipofisarias, en particular la acromegalia, el hipertiroidismo, el hipotiroidismo y las alteracionessuprarrenales, como son la enfermedad de Cushing, el hiperaldosteronismo y el feocromocitoma, están asociadas con la aparición de insuficiencia cardíaca, cardiopatía dilatada, arritmiascardíacas, e incluso, muerte súbita. La siguiente revisión pretende explicar de forma clara y precisa las principales cardiopatías de origen endocrinológico.
 
Publisher EDIMECO S.A.
 
Date 2020-06-30
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
 
Format application/pdf
 
Identifier https://medicinaylaboratorio.com/index.php/myl/article/view/298
10.36384/01232576.298
 
Source Medicina & Laboratorio; Vol. 24 No. 3 (2020): Julio-Septiembre; 207-220
Medicina y Laboratorio; Vol. 24 Núm. 3 (2020): Julio-Septiembre; 207-220
2500-7106
0123-2576
 
Language spa
 
Relation https://medicinaylaboratorio.com/index.php/myl/article/view/298/294
/*ref*/Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol 2016;13:368-378. https://doi.org/10.1038/nrcardio.2016.25. 2. Ciapponi A, Alcaraz A, Calderón M, Matta MG, Chaparro M, Soto N, et al. Carga de enfermedad de la insuficiencia cardiaca en América Latina: revisión sistemática y metanálisis. Rev Esp Cardiol 2016;69:1051–1060. https://doi.org/https://doi.org/10.1016/j.recesp.2016.04.045. 3. Gómez E. Capítulo 2. Introducción, epidemiología de la falla cardiaca e historia de las clínicas de falla cardiaca en Colombia. Rev Colomb Cardiol 2016;23:6-12. https://doi.org/https://doi.org/10.1016/j.rccar.2016.01.004. 4. Bocchi EA, Arias A, Verdejo H, Diez M, Gomez E, Castro P, et al. The reality of heart failure in Latin America. J Am Coll Cardiol 2013;62:949-958. https://doi.org/10.1016/j.jacc.2013.06.013. 5. Mirzababaei A, Djafarian K, Mozafari H, Shab-Bidar S. The long-term prognosis of heart diseases for different metabolic phenotypes: a systematic review and meta-analysis of prospective cohort studies. Endocrine 2019;63:439-462. https://doi.org/10.1007/s12020-019-01840-0. 6. Rhee SS, Pearce EN. The endocrine system and the heart: A review. Rev Esp Cardiol 2011;64:220-231. https://doi.org/10.1016/j.rec.2010.10.016 7. García-Lled´ JA. La afectación cardíaca en las enfermedades endocrinológicas. Rev Clin Esp 2000;200:566-569. https://doi.org/https://doi.org/10.1016/S0014-2565(00)70721-1. 8. Colao A, Grasso LFS, Giustina A, Melmed S, Chanson P, Pereira AM, et al. Acromegaly. Nat Rev Dis Primers 2019;5:20. https://doi.org/10.1038/s41572-019-0071-6. 9. AlDallal S. Acromegaly: a challenging condition to diagnose. Int J Gen Med 2018;11:337-343. https://doi.org/10.2147/IJGM.S169611. 10. Zahr R, Fleseriu M. Updates in diagnosis and treatment of acromegaly. Eur Endocrinol 2018;14:57-61. https://doi.org/10.17925/EE.2018.14.2.57. 11. Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JAH, et al. A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol 2018;14:552-561. https://doi.org/10.1038/s41574-018-0058-5. 12. Vilar L, Vilar CF, Lyra R, Lyra R, Naves LA. Acromegaly: clinical features at diagnosis. Pituitary 2017;20:22-32. https://doi.org/10.1007/s11102-016-0772-8. 13. Guo X, Fu H, Pang H, Xing B. Risk of left ventricular hypertrophy and diastolic and systolic dysfunction in acromegaly: A meta-analysis. J Clin Neurosci 2018;48:28-33. https://doi.org/10.1016/j.jocn.2017.10.067. 14. Sharma AN, Tan M, Amsterdam EA, Singh GD. Acromegalic cardiomyopathy: Epidemiology, diagnosis, and management. Clinical cardiology 2018;41:419-425. https://doi.org/10.1002/clc.22867. 15. Ramos-Levi AM, Marazuela M. Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management. Endocrine 2017;55:346-359. https://doi.org/10.1007/s12020-016-11913. 16. Goldberg MD, Vadera N, Yandrapalli S, Frishman WH. Acromegalic cardiomyopathy: An overview of risk factors, clinical manifestations, and therapeutic options. Cardiol Rev 2018;26:307-311. https://doi.org/10.1097/CRD.0000000000000215. 17. Mantri NM, Amsterdam E, Tan M, Singh GD. Power failure: Acromegalic cardiomyopathy. Am J Med 2016;129:674-677. https://doi.org/10.1016/j.amjmed.2016.02.041. 18. Sharma MD, Nguyen AV, Brown S, Robbins RJ. Cardiovascular disease in acromegaly. Methodist Debakey Cardiovasc J 2017;13:64-67. https://doi.org/10.14797/mdcj-13-2-64. 19. Gutiérrez-Restrepo J, Sierra-Latorre G, Campuzano-Maya G. Síndrome de Cushing. Med Lab 2009;15:411-430. 20. Pappachan JM, Hariman C, Edavalath M, Waldron J, Hanna FW. Cushing’s syndrome: a practical approach to diagnosis and differential diagnoses. J Clin Pathol 2017;70:350-359. https://doi.org/10.1136/jclinpath-2016-203933. 21. Bansal V, El Asmar N, Selman WR, Arafah BM. Pitfalls in the diagnosis and management of Cushing’s syndrome. Neurosurg Focus 2015;38:E4. https://doi.org/10.3171/2014.11.Focus14704. 22. Findling JW, Raff H, Aron DC. The low-dose dexamethasone suppression test: a reevaluationin patients with Cushing’s syndrome. J Clin Endocrinol Metab 2004;89:1222-1226. https://doi.org/10.1210/jc.2003-030207. 23. Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, et al. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008;93:1526-1540. https://doi.org/10.1210/jc.2008-0125. 24. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, et al. Accuracy of diagnostic tests for Cushing’s syndrome: a systematic review and metaanalyses. J Clin Endocrinol Metab 2008;93:1553-1562. https://doi.org/10.1210/jc.2008-0139. 25. Nieman LK. Recent updates on the diagnosis and management of Cushing’s syndrome. Endocrinol Metab (Seoul) 2018;33:139-146. https://doi.org/10.3803/EnM.2018.33.2.139. 26. Loriaux DL. Diagnosis and differential diagnosis of Cushing’s syndrome. N Engl J Med 2017;376:1451-1459. https://doi.org/10.1056/NEJMra1505550. 27. Nieman LK. Diagnosis of Cushing’s syndrome in the modern era. Endocrinol Metab Clin North Am 2018;47:259-273. https://doi.org/10.1016/j.ecl.2018.02.001. 28. Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, et al. Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 2008;93:2454-2462. https://doi.org/10.1210/jc.2007-2734. 29. Whitworth JA, Mangos GJ, Kelly JJ. Cushing, cortisol, and cardiovascular disease. Hypertension 2000;36:912-916. https://doi.org/10.1161/01.hyp.36.5.912. 30. Shibusawa N, Yamada M, Hashida T, Hashimoto K, Satoh T, Horiguchi J, et al. Dilated cardiomyopathy as a presenting feature of Cushing’s syndrome. Intern Med 2013;52:1067-1071. https://doi.org/10.2169/internalmedicine.52.9051. 31. Kamenicky P, Redheuil A, Roux C, Salenave S, Kachenoura N, Raissouni Z, et al. Cardiac structure and function in Cushing’s syndrome: a cardiac magnetic resonance imaging study. J Clin Endocrinol Metab 2014;99:E2144-2153. https://doi.org/10.1210/jc.2014-1783. 32. Aydogan BI, Gerede DM, Canpolat AG, Erdogan MF. Cushing’s disease presented by reversible dilated cardiomyopathy. Case Rep Cardiol 2015;2015:980897. https://doi.org/10.1155/2015/980897. 33. Marchand L, Segrestin B, Lapoirie M, Favrel V, Dementhon J, Jouanneau E, et al. Dilated cardiomyopathy revealing Cushing disease: A case report and literature review. Medicine (Baltimore) 2015;94:e2011. https://doi.org/10.1097/MD.0000000000002011. 34. De Leo M, Pivonello R, Auriemma RS, Cozzolino A, Vitale P, Simeoli C, et al. Cardiovascular disease in Cushing’s syndrome: heart versus vasculature. Neuroendocrinology 2010;92 Suppl 1:50-54. https://doi.org/10.1159/000318566. 35. Brown SJ, Ruppe MD, Tabatabai LS. The parathyroid gland and heart disease. Methodist Debakey Cardiovasc J 2017;13:49-54. https://doi.org/10.14797/mdcj-13-2-49. 36. Fraser WD. Hyperparathyroidism. Lancet 2009;374:145-158. https://doi.org/10.1016/S0140-6736(09)60507-9. 37. Walker MD, Silverberg SJ. Primary hyperparathyroidism. Nat Rev Endocrinol 2018;14:115-125. https://doi.org/10.1038/nrendo.2017.104. 38. Guimaraes T, Nobre-Menezes M, Cruz D, do Vale S, Bordalo A, Veiga A, et al. Hypercalcemic crisis and primary hyperparathyroidism: Cause of an unusual electrical storm. Rev Port Cardiol 2017;36:959 e951-959 e955. https://doi.org/10.1016/j.repc.2016.12.015. 39. Dokupilova A, Payer J. 24-hour outpatient ECG as a screening method in patients with primary hyperparathyroidism. Bratisl Lek Listy 2016;117:495-500. https://doi.org/10.4149/bll_2016_096. 40. Pepe J, Cipriani C, Curione M, Biamonte F, Colangelo L, Danese V, et al. Reduction of arrhythmias in primary hyperparathyroidism, by parathyroidectomy, evaluated with 24-h ECG monitoring. Eur J Endocrinol 2018;179:117-124. https://doi.org/10.1530/EJE-17-0948. 41. Skaaby T, Thuesen BH, Linneberg A. Vitamin D, cardiovascular disease and risk factors. Adv Exp Med Biol 2017;996:221-230. https://doi.org/10.1007/978-3-319-56017-5_18. 42. Mannstadt M, Bilezikian JP, Thakker RV, Hannan FM, Clarke BL, Rejnmark L, et al. Hypoparathyroidism. Nat Rev Dis Primers 2017;3:17055. https://doi.org/10.1038/nrdp.2017.55. 43. Vargas-Uricoechea H, Bonelo-Perdomo A, Sierra-Torres CH. Effects of thyroid hormones on the heart. Clin Investig Arterioscler 2014;26:296-309. https://doi.org/10.1016/j.arteri.2014.07.003. 44. Ademolu A. Thyrotoxic cardiomyopathy: A study of three cases. Gerontol Geriatr Stud 2017;1:46-49. https://doi.org/10.31031/GGS.2017.01.000512. 45. Oliveros-Ruiz L VM, Diez-Canseco LF, Cárdenas M, Hermosillo JAG,. Determinants of thyrotoxic cardiomyopathy recovery. Bio Med Res Int 2013;2013:1-7. https://doi.org/10.1155/2013/452709 46. Al-Ghamdi AS, Aljohani N. Graves’ thyrotoxicosis-induced reversible cardiomyopathy: a case report. Clin Med Insights Case Rep 2013;6:47-50. https://doi.org/10.4137/CCRep.S10534. 47. Osuna PM, Udovcic M, Sharma MD. Hyperthyroidism and the heart. Methodist Debakey Cardiovasc J 2017;13:60-63. https://doi.org/10.14797/mdcj-13-2-60. 48. Baladi IH, Rai AA, Ahmed SM. ECG changes in patients with primary hyperthyroidism. Pan Afr Med J 2018;30:246. https://doi.org/10.11604/pamj.2018.30.246.12244. 49. Udovcic M, Pena RH, Patham B, Tabatabai L, Kansara A. Hypothyroidism and the heart. Methodist Debakey Cardiovasc J 2017;13:55-59. https://doi.org/10.14797/mdcj-13-2-55. 50. Vargas-Uricoechea H, Bonelo-Perdomo A. Thyroid dysfunction and heart failure: Mechanisms and associations. Curr Heart Fail Rep 2017;14:48-58. https://doi.org/10.1007/s11897-017-0312-5. 51. Toft AD, Boon NA. Thyroid disease and the heart. Heart 2000;84:455-460. https://doi.org/10.1136/heart.84.4.455. 52. Klein I, Danzi S. Thyroid disease and the heart. Curr Probl Cardiol 2016;41:65-92. https://doi.org/10.1016/j.cpcardiol.2015.04.002. 53. Bielecka-Dabrowa A, Godoy B, Suzuki T, Banach M, von Haehling S. Subclinical hypothyroidism and the development of heart failure: an overview of risk and effects on cardiac function. Clin Res Cardiol 2019;108:225-233. https://doi.org/10.1007/s00392-018-1340-1. 54. Razvi S, Jabbar A, Pingitore A, Danzi S, Biondi B, Klein I, et al. Thyroid hormones and cardiovascular function and diseases. J Am Coll Cardiol 2018;71:1781-1796. https://doi.org/10.1016/j.jacc.2018.02.045. 55. Binu A, Cherian K, Kapoor N, Chacko S, George O, Paul T. The heart of the matter: Cardiac manifestations of endocrine disease. Indian J Endocrinol Metab 2017;21:919-925. https://doi.org/10.4103/ijem.IJEM_212_17. 56. Botero-Arango A, Duque-Ramírez M, Duque-González L. Deficiencia de andrógenos y enfermedad cardiovascular en el hombre. Med Lab 2014;20:43-56.
 
Rights https://creativecommons.org/licenses/by-nc-nd/4.0
 

Contact Us

The PKP Index is an initiative of the Public Knowledge Project.

For PKP Publishing Services please use the PKP|PS contact form.

For support with PKP software we encourage users to consult our wiki for documentation and search our support forums.

For any other correspondence feel free to contact us using the PKP contact form.

Find Us

Twitter

Copyright © 2015-2018 Simon Fraser University Library